



Contact:  
David Waldman or Justyna Gudaszevska  
Crescendo Communications, LLC  
Email: [mmd@crescendo-ir.com](mailto:mmd@crescendo-ir.com)  
Tel: +48 693 354 580

### **Milestone Medical Announces Successful Epidural Steroid Injection Procedures Under New AMA CPT Guidelines for Artificial Intelligence (AI) Assisted Pain Management Surgery**

**Roseland, NJ., May 10, 2023 – Milestone Medical Inc. (WAR: MMD, “the Company”)** today announced the successful completion of the first series of epidural steroid injections (ESI) using the CompuFlo Epidural System by physicians under the new American Medical Association (AMA) Current Procedural Terminology (CPT®) guidelines for AI-assisted analgesic epidural needle placement in patients.

The AMA’s new technology-specific Category III CPT® code, which came into effect in the CPT codebook on January 1, 2023, specifically covers technologies that “integrate AI to place an epidural needle.” The published and copyrighted guidelines further note that the technology must include real-time software to assist the physician by transmitting key data points, along with sensors to interpret epidural pressures, detail anatomical needle placement, and measure precise saline volume via software facilitating data transmission to an epidural system console screen. The Company is not aware of any systems, other than the CompuFlo Epidural System, that would meet these criteria. Additionally, the technology is backed by a broad portfolio of domestic and international patents.

Arjan Haverhals, CEO of Milestone Medical, stated, “We are proud to announce that multiple physicians have now completed ESI procedures using the CompuFlo Epidural System under the new AMA CPT guidelines for AI-assisted epidural needle placement. This is an important milestone, as it further validates the medical importance of the CompuFlo Epidural System by these physicians in their plans of treatment. Specifically, our proprietary and highly accurate AI-assisted technology enhances both the efficacy and safety of pain management surgery. We believe this data will play an important role as we seek reimbursement for the CompuFlo Epidural System under the new CPT® code.”

#### **About Milestone Medical Inc.**

Milestone Medical, Inc. (WAR:MMD) has developed epidural and intra-articular drug delivery systems based on a patented, painless, computer-controlled injection and drug delivery technology originally developed by Milestone Scientific, Inc. Development of both the epidural and intra-articular instruments is now complete. The Company was granted the FDA marketing clearance of the epidural instrument in U.S. and is currently pursuing regulatory approval for intra-articular instrument in the U.S. Milestone Medical received CE Mark approval to sell and market its intra-articular and epidural instruments across European Union. For more information please visit [www.medicalmilestone.com](http://www.medicalmilestone.com).

#### **About Milestone Scientific Inc.**

Milestone Scientific Inc. (MLSS), a technology-focused medical research and development company that patents, designs and develops innovative injection technologies and instruments for medical, dental and cosmetic applications. Milestone Scientific’s computer-controlled systems are

designed to make injections precise, efficient and increase the overall patient comfort and safety. Their proprietary DPS Dynamic Pressure Sensing Technology® instruments is the platform to advance the development of next-generation devices, regulating flow rate and monitoring pressure from the tip of the needle, through platform extensions of subcutaneous drug delivery, including local anesthetic. To learn more, view the [MLSS brand video](#) or visit [milestonescientific.com](http://milestonescientific.com).

**Safe Harbor Statement**

*This press release contains forward-looking statements regarding the timing and financial impact of Milestone's ability to implement its business plan, expected revenues, timing of regulatory approvals and future success. These statements involve a number of risks and uncertainties and are based on assumptions involving judgments with respect to future economic, competitive and market conditions, future business decisions and regulatory developments, all of which are difficult or impossible to predict accurately and many of which are beyond Milestone's control. Some of the important factors that could cause actual results to differ materially from those indicated by the forward-looking statements are general economic conditions, failure to achieve expected revenue growth, changes in our operating expenses, adverse patent rulings, FDA or legal developments, competitive pressures, changes in customer and market requirements and standards, and the risk factors detailed from time to time in Milestone's periodic filings with the Securities and Exchange Commission, including without limitation, Milestone's Annual Report for the year ended December 31, 2022. The forward-looking statements in this press release are based upon management's reasonable belief as of the date hereof. Milestone undertakes no obligation to revise or update publicly any forward-looking statements for any reason.*